2093eTiP An open-label phase II study of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with advanced NSCLC harbouring EGFR mutations categorised according to structural based classification
作者
K. Sooi,J.L. Low,Y. Ang,Y. Huang,Jorn Nützinger,M. Sachdeva,K.N. Tan,R.A. Soo